NovaCina is the Perth-based manufacturing arm of holding company Bridgewest Perth Pharma, part of the private US investment company Bridgewest Group. It was established in 2023 after Bridgewest Group purchased the sterile injectable manufacturing facility of Pfizer (Perth), a subsidiary of Pfizer Inc.
NovaCina, a contract development and manufacturing organisation, is involved in early-stage drug development to full-scale manufacturing and advanced analytical studies. It supplies drug products to over 90 countries globally, with approvals secured by regulatory bodies including the United States Food and Drug Administration, the Therapeutic Goods Administration, and the EU.